Announcement from Össur hf. No. 78/2016
Reykjavik, 29 August 2016
Today, Össur hf. has granted 775,000 share options; 225,000 to each executive; Mr. Egill Jónsson, EVP Manufacturing and Operations, Mr. Ólafur Gylfason, EVP Sales and Dr. Þorvaldur Ingvarsson, EVP Research and Development. Also, 100,000 were granted to middle management.
The exercise price is DKK 26.84, i.e. the Company's average share price on NASDAQ Copenhagen 20 trading days prior to the grant date. First exercise date is 29 August 2019.
Mr. Egill Jonsson holds 822,749 shares in Össur and previously had 225,000 share options, Mr. Ólafur Gylfason holds 9,517 shares in Össur and had 225,000 share options, Dr Þorvaldur Ingvarsson holds 19,795 shares in Össur and had 225,000 share options.
The share options were granted in accordance with the Company's share option scheme implemented on 27 May 2015. Further details on the share option scheme, including the key terms and conditions, can be found in the Company's announcement No. 24/2015 published on 27 May 2015.
Össur press releases by e-mail: If you wish to receive Össur press releases by e-mail please register at the following web-site: http://www.ossur.com/investormailings.
Össur (NASDAQ: OSSR) is a global leader in non-invasive orthopaedics that help people live a life without limitations. Its business is focused on improving people's mobility through the delivery of innovative technologies within the fields of braces, supports and prosthetic limbs. A recognized "Technology Pioneer", Össur invests significantly in research and product development; its award-winning designs ensuring a consistently strong position in the market. Successful patient and clinical outcomes are further empowered via Össur's educational programs and business solutions. Headquartered in Iceland, Össur has major operations in the Americas, Europe and Asia, with additional distributors worldwide. www.ossur.com
This press release includes "forward-looking statements" which involve risks and uncertainties that could cause actual results to differ materially from results expressed or implied by these statements. Össur hf. undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.
Last updated on: 31/08/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.